Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (vol 22, pg 693, 2021)

被引：1
|
作者：
Simpson, Eric L. [1 ]
Silverberg, Jonathan I. [2 ]
Nosbaum, Audrey [3 ]
Winthrop, Kevin L. [1 ]
Guttman-Yassky, Emma [4 ]
Hoffmeister, Karin M. [5 ,6 ]
Egeberg, Alexander [7 ]
Valdez, Hernan [8 ]
Zhang, Min [9 ]
Farooqui, Saleem A. [10 ]
Romero, William [11 ]
Thorpe, Andrew J. [12 ]
Rojo, Ricardo [13 ]
Johnson, Susan [12 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
[3] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Allergy & Clin Immunol, Pierre Benite, France
[4] Icahn Sch Med Mt Sinai, Dept Dermatol & Immunol, New York, NY 10029 USA
[5] Blood Res Inst, Versiti Translat Glyc Ctr, Milwaukee, WI USA
[6] Med Coll Wisconsin, Dept Biochem & Med, Milwaukee, WI 53226 USA
[7] Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[8] Pfizer Inc, New York, NY USA
[9] Pfizer Inc, La Jolla, CA USA
[10] Pfizer R&D UK Ltd, Kent, OH USA
[11] Pfizer Ltd, Surrey, England
[12] Pfizer Inc, Collegeville, PA 19426 USA
[13] Pfizer Inc, Groton, CT 06340 USA
来源：
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY | 2021年 / 22卷 / 06期
关键词：
D O I：
10.1007/s40257-021-00638-z
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：905 / 905
页数：1
相关论文
共 50 条
  • [1] Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
    Eric L. Simpson
    Jonathan I. Silverberg
    Audrey Nosbaum
    Kevin L. Winthrop
    Emma Guttman-Yassky
    Karin M. Hoffmeister
    Alexander Egeberg
    Hernan Valdez
    Min Zhang
    Saleem A. Farooqui
    William Romero
    Andrew J. Thorpe
    Ricardo Rojo
    Susan Johnson
    [J]. American Journal of Clinical Dermatology, 2021, 22 : 693 - 707
  • [2] Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Nosbaum, Audrey
    Winthrop, Kevin L.
    Guttman-Yassky, Emma
    Hoffmeister, Karin M.
    Egeberg, Alexander
    Valdez, Hernan
    Zhang, Min
    Farooqui, Saleem A.
    Romero, William
    Thorpe, Andrew J.
    Rojo, Ricardo
    Johnson, Susan
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (05) : 693 - 707
  • [3] Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
    Eric L. Simpson
    Jonathan I. Silverberg
    Audrey Nosbaum
    Kevin L. Winthrop
    Emma Guttman-Yassky
    Karin M. Hoffmeister
    Alexander Egeberg
    Hernan Valdez
    Min Zhang
    Saleem A. Farooqui
    William Romero
    Andrew J. Thorpe
    Ricardo Rojo
    Susan Johnson
    [J]. American Journal of Clinical Dermatology, 2021, 22 : 905 - 905
  • [4] Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial programme
    Simpson, E. L.
    Silverberg, J. I.
    Nosbaum, A.
    Winthrop, K.
    Guttman-Yassky, E.
    Hoffmeister, K. M.
    Zhang, M.
    Farooqui, S. A.
    Johnson, S.
    Thorpe, A.
    Rojo, R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E133 - E134
  • [5] Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Nosbaum, Audrey
    Winthrop, Kevin
    Guttman-Yassky, Emma
    Hoffmeister, Karin M.
    Zhang, Min
    Farooqui, Saleem A.
    Johnson, Susan
    Thorpe, Andrew
    Rojo, Ricardo
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB150 - AB150
  • [6] Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Johnson, Susan
    Lazariciu, Irina
    Koppensteiner, Herwig
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 77
  • [7] Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB72 - AB72
  • [8] Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program
    Eichenfield, Lawrence F.
    Flohr, Carsten
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Nesnas, John
    Koppensteiner, Herwig
    Zhang, Fan
    Rojo, Ricardo
    Chan, Gary
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [9] Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Gooderham, Melinda
    Chan, Gary
    Feeney, Claire
    Biswas, Pinaki
    Valdez, Hernan
    DiBonaventura, Marco
    Nduaka, Chudy
    Rojo, Ricardo
    [J]. JAMA DERMATOLOGY, 2020, 156 (08) : 863 - 873
  • [10] Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial programme
    Eichenfield, L. F.
    Flohr, C.
    Bangert, C.
    Irvine, A. D.
    Weidinger, S.
    Nesnas, J.
    Koppensteiner, H.
    Zhang, F.
    Rojo, R.
    Chan, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E142 - E143
12345